Nirsevimab is associated with a 62% reduction in the odds of all-cause lower respiratory tract infection (LRTI) hospitalizations in infants.
The monoclonal antibody reduced RSV-related emergency department (ED) visits by 76%, highlighting its specific efficacy against its primary target.
Real-world data from 11 studies across five countries corroborate the high efficacy observed in earlier clinical trials like MELODY and HARMONIE.
While respiratory-specific outcomes improved significantly, all-cause hospitalization rates did not show a statistically significant difference, reflecting the diverse etiology of infant admissions.
